NHFPartnerSpotlight: Askingthetoughquestions tosupporttherareblooddisorderscommunity

What if we could ….

Help improve access to hemophilia treatments around the world? Work together to address health equity challenges?

Change the treatment paradigm for people living with rare blood disorders?

Every day, Sanofi employees ask what if…? And we work together on solutions that can improve people’s lives by chasing the miracles of science and making the impossible possible. Sanofi has been involved in the rare disease space for more than 35 years and our commitment to give our all to support the community has never wavered.

Patients

AND SCIENCE ARE AT THE CENTER OF EVERYTHING WE DO AT SANOFI

What if we could create a more equitable patient experience?

At Sanofi, we believe every person should have the opportunity to be as healthy as possible. We aim to accelerate health equity so all patients have access to potentially transformative medicines. We realize that to enact meaningful change that we need to partner across organizations on these efforts. We appreciate the opportunity to partner in NHF’s Health Equity, Diversity & Inclusion Initiative and to work together to advocate for underrepresented communities. Sanofi has also introduced two programs to address health equity challenges with out-of-the-box solutions.

Annual Health Equity Accelerator Awards that support the efforts of US advocacy groups to address specific challenges impacting underserved populations. Our 2023 hemophilia-focused challenges are: 1) Provide education and support for people in rural areas, and 2) Improve diagnosis and care delivery for women, girls, or persons with the potential to menstruate with below-normal factor levels.

Health Equity Acceleration Community of Practice provides a forum that brings together 150+ US-based advocacy leaders across all therapeutic areas in which Sanofi engages to make connections, inspire learning, and share best practices.

What if we could advance science to redefine hemophilia?

Sanofi has a deep-rooted commitment to patient-centered research and development (R&D) and we realize we need partners to gather the insights that can help lead to impactful medicines. That’s why, along with other industry and patient advocacy groups, we’re excited to have launched PALADIN, a first-of-itskind R&D Consortium, which aims to accelerate medicines development regardless of disease within the U.S. ecosystem. We are proud to have NHF CEO Dr. Leonard Valentino serving on the Executive Committee.

We have also partnered with NHF on various other scientific research efforts including sponsoring the Gene Therapy & Novel Technologies Workshop and participating in State of the Science working groups. We look forward to supporting and engaging in NHF’s launch of a National Research Blueprint in early 2024.

Sanofi has also helped elevate treatment expectations in rare blood disorders by advancing science and developing first-in-class treatment options. Our quest to push the boundaries of scientific innovation continues as we explore new approaches for people with hemophilia A and B.

Learn more about our commitment at redefininghemophilia.com.

MAT-US-2304359-v1.0-05/2023

© 2023 Genzyme Corporation. All rights reserved.